Oncobiologics and InVentive Health Clinical Form Biosimilars Pact Pharmaceutical Technology Magazine The current biosimilar assets include generic versions of Humira (adalimumab), Rituxan (rituximab), Avastin (bevacizumab), Herceptin (trastuzumab), and Erbitux (cetuximab). This is the third biosimilar agreement Oncobiologics has formed this year. In ... |
